SB-243213

SB-243213 is a drug that acts as a selective 5-HT2C receptor antagonist. It has been researched for potential use in the treatment of schizophrenia, obesity, and sexual dysfunction, but has not been developed for medical use.

Pharmacology

SB-243213 is a potent and selective antagonist of the 5-HT2C receptor. This receptor is a subtype of the 5-HT2 receptor family that responds to the neurotransmitter serotonin. Antagonism of the 5-HT2C receptor is thought to have potential therapeutic applications in a number of conditions, including schizophrenia, obesity, and sexual dysfunction.

Research

Preclinical studies have shown that SB-243213 can enhance the effects of antipsychotic drugs in animal models of schizophrenia. It has also been shown to reduce food intake and body weight in obese rats, suggesting potential use in the treatment of obesity. In addition, it has been found to improve sexual function in rats, indicating potential use in the treatment of sexual dysfunction.

Development

Despite the promising results of preclinical studies, SB-243213 has not been developed for medical use. The reasons for this are not clear, but may include difficulties in drug formulation, lack of efficacy in clinical trials, or commercial considerations.

See also

• 5-HT2C receptor
• Antipsychotic
• Obesity
• Sexual dysfunction

SB-243213 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia